Rituximab for adult ITP: Conclusions

• Responses 50%-60%

• Durable CR ~30%

• Equally effective in splenectomized and non-splenectomized patients

• Patients with a CR have a more durable B-cell depletion

• Possibility of second responses

• ITP duration prior to rituximab therapy predicts both CR and CR duration

Previous slide

Back to first slide

View graphic version